Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
Sponsor: China Medical University Hospital
Summary
sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2024-09-23
Completion Date
2029-03
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
S1RA plus NMDAE
Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.
S1RA plus Placebo Cap
Use of an S1R agonist plus placebo as a comparator
Locations (1)
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan